Sun Pharmaceutical Industries Ltd

Sun Pharmaceutical Industries Ltd

Health CarePharmaceuticals & Biotechnology
  • Price (INR)390.75
  • Today's Change-35.80 / -8.39%
  • Shares traded82.91m
  • 1 Year change-32.27%
  • Beta0.2368
Data delayed at least 15 minutes, as of Jan 18 2019 10:29 GMT.
More ▼

Profile data is unavailable for this security.

About the company

Sun Pharmaceutical Industries Limited is a pharmaceuticals company. The Company's business segments include US Business, Indian Branded Generics Business, Emerging Markets, Global Consumer Healthcare Business and Active Pharmaceutical Ingredients (API). Its Rest of World segment includes Western Europe, Canada, Australia, New Zealand and other markets. The Company offers its products to therapy areas, such as cardiology, neuro-psychiatry, gastroenterology, anti-infective, diabetology and dermatology. The Company's products include AB PHYLLINE, ABZORB DUSTING POWDER, ACAMPROL, ACOSTIN 3 MIU, ACOSTIN FORTE and AB PHYLLINE SR 200. Its manufacturing units are situated in India, the United States and Brazil, among others. Its units produce generics, branded generics, specialty products, over-the-counter (OTC) products, anti-retroviral (ARVs) and APIs. They also produce intermediates in a range of dosage forms, including tablets, capsules, injectables, ointments, creams and liquids.

  • Revenue in INR (TTM)277.92bn
  • Net income in INR26.92bn
  • Incorporated1993
  • Employees30.00k
  • Location
    Sun Pharmaceutical Industries LtdAcme PlazaAndheri Kurla Road, Andheri EastMUMBAI 400093IndiaIND
  • Phone+91 2 243244324
  • Fax+91 2 652354897
  • Websitehttp://www.sunpharma.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Alkem Laboratories Ltd68.42bn6.29bn226.84bn13.27k36.054.3427.973.3252.6452.64572.23437.050.902.095.525,156,051.008.4811.2612.0016.7360.9455.759.4312.901.1715.390.210413.039.8920.85-29.2710.4523.83--
GlaxoSmithKline Pharmaceuticals Limited14.61bn3.38bn240.17bn4.62k73.32--204.6916.4419.3419.3493.64--------3,161,286.00--------23.80--23.12-----------3.48--4.13------
Torrent Pharmaceuticals Ltd69.51bn6.28bn321.14bn15.60k51.016.8127.334.6237.2137.21411.55278.530.55391.105.224,456,055.005.0011.667.8018.0071.7968.939.0317.410.63182.510.604429.931.5913.13-27.379.3921.9916.59
Cadila Healthcare Ltd123.53bn20.31bn355.29bn11.82k17.503.9913.772.8819.8319.66120.6987.000.71511.794.5110,451,480.0011.5812.9417.3120.0566.1660.3116.1915.300.88974.510.411420.1324.8913.4620.4122.397.7018.47
Biocon Ltd46.72bn6.97bn386.18bn5.01k55.746.8632.558.2711.7011.7078.5095.060.44672.234.719,335,065.007.487.309.919.6361.9153.5316.7415.571.3511.000.310817.175.3110.69-39.16-6.0520.47-9.71
Lupin Limited157.90bn-930.70m390.11bn17.04k--2.8939.262.47-2.07-2.07348.46298.760.57671.533.139,265,215.00-0.306410.42-0.387913.6864.5861.54-0.531413.141.585.890.385617.41-9.6610.39-90.18-28.1723.034.56
Divi's Laboratories Ltd-100.00bn-100.00bn400.63bn10.66k--------------------------19.44--22.06--53.95--26.83------28.31-4.7112.78-17.307.82-4.245.92
Cipla Ltd155.63bn14.07bn410.41bn23.61k29.202.7815.202.6417.4517.45192.96183.070.6681.434.286,591,563.005.887.387.319.8064.3756.928.8110.021.9511.910.256512.664.0312.9540.16-1.801.528.45
Piramal Enterprises Ltd118.96bn48.47bn421.58bn6.84k8.641.618.363.54265.88265.88631.361,425.580.17341.7310.5217,384,200.006.665.4311.188.2787.2777.7838.4026.110.26451.560.672124.5924.4824.76308.96--21.117.52
Dr.Reddy's Laboratories Ltd149.42bn16.96bn431.23bn23.52k25.453.2815.592.89102.0594.42899.03790.700.65851.383.396,351,811.007.329.1310.6014.0172.5669.9311.1212.011.1323.630.360919.620.5983.72-16.90-6.807.885.92
Sun Pharmaceutical Industries Limited277.92bn26.92bn937.54bn30.00k34.822.2919.403.3711.2210.16115.83170.980.41131.093.289,264,043.004.7510.787.6916.1172.1769.3311.5519.801.179.100.240710.70-16.1218.58-65.31-4.1717.42-4.36
Data as of Jan 18 2019. Currency figures normalised to Sun Pharmaceutical Industries Ltd's reporting currency: Indian Rupee INR

Institutional shareholders

18.47%Per cent of shares held by top holders
HolderShares% Held
Life Insurance Corp. of Indiaas of 30 Sep 2018142.65m5.95%
ICICI Prudential Asset Management Co. Ltd.as of 31 Dec 201883.04m3.46%
The Vanguard Group, Inc.as of 31 Dec 201837.23m1.55%
SBI Funds Management Pvt Ltd.as of 31 Dec 201833.79m1.41%
GIC Pte Ltd. (Investment Management)as of 30 Sep 201832.63m1.36%
Reliance Nippon Life Asset Management Ltd. (Invt Mgmt)as of 31 Dec 201828.78m1.20%
Matthews International Capital Management LLCas of 30 Sep 201826.00m1.08%
BlackRock Fund Advisorsas of 02 Jan 201925.85m1.08%
UTI Asset Management Co. Ltd. (Investment Management)as of 31 Dec 201818.34m0.76%
Kotak Mahindra Asset Management Co. Ltd.as of 31 Dec 201814.94m0.62%
More ▼
Data from 30 Sep 2018 - 16 Jan 2019Source: FactSet Research Systems Inc.
© Thomson Reuters Click for restrictions
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.